- 2023, Volume 81 - Number 1
- Published: March 24, 2023
Erythema multiforme caused by topical imiquimod 3.75%
César Magalhães 1, André Coelho 2, Miguel Costa 1, Nuno Menezes 1
1 Dermatology Service, Centro Hospitalar Vila Nova de Gaia/Espinho, Porto, Portugal; 2 Department of Pathological Anatomy. Centro Hospitalar Universitário de Santo António, Porto, Portugal
César Magalhães, André Coelho, Miguel Costa, Nuno Menezes
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: André Coelho, Email not available
Abstract
Imiquimod, 3.75% cream, is a topical immunomodulator approved for treating actinic keratoses. Although local side effects are more frequent, it can also have systemic side effects. We report that imiquimod 3.75% can also produce erythema multiforme (EM), thus discarding it as an alternative to imiquimod 5% on this adverse effect.
